Abstract | BACKGROUND: OBJECTIVES: To evaluate the efficacy and safety of lebrikizumab monotherapy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) over 52 weeks of treatment in ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). METHODS: Patients who responded to lebrikizumab 250 mg every 2 weeks (Q2W) at the end of the 16-week induction period were re-randomized 2 : 2 : 1 to receive lebrikizumab Q2W, lebrikizumab 250 mg every 4 weeks (Q4W) or placebo Q2W ( lebrikizumab withdrawal) for 36 additional weeks. Response at week 16 was defined as achieving a 75% reduction in Eczema Area Severity Index (EASI 75) or an Investigator's Global Assessment ( IGA) of 0 or 1, with a ≥ 2-point improvement and no rescue medication use. Multiple imputation was used to handle missing data. Intermittent use of topical therapy was permitted during the maintenance period. RESULTS: After 52 weeks, an IGA of 0 or 1 with a ≥ 2 point improvement was maintained by 71.2% of patients treated with lebrikizumab Q2W, 76.9% of patients treated with lebrikizumab Q4W and 47.9% of patients in the lebrikizumab withdrawal arm. EASI 75 was maintained by 78.4% of patients treated with lebrikizumab Q2W, 81.7% of patients treated with lebrikizumab Q4W and 66.4% of patients in the lebrikizumab withdrawal arm at week 52. Across treatment arms, proportions of patients using any rescue therapy were 14.0% (ADvocate1) and 16.4% (ADvocate2). During the combined induction and maintenance periods of ADvocate1 and ADvocate2, 63.0% of lebrikizumab-treated patients reported any treatment emergent adverse event, with most events (93.1%) being mild or moderate in severity. CONCLUSIONS: After a 16-week induction period with lebrikizumab Q2W, lebrikizumab Q2W and Q4W maintained similar improvement of the signs and symptoms of moderate-to-severe AD, with a safety profile consistent with previously published data.
|
Authors | Andrew Blauvelt, Jacob P Thyssen, Emma Guttman-Yassky, Thomas Bieber, Esther Serra-Baldrich, Eric Simpson, David Rosmarin, Hany Elmaraghy, Eric Meskimen, Chitra R Natalie, Zhuqing Liu, Chenjia Xu, Evangeline Pierce, MaryAnn Morgan-Cox, Esther Garcia Gil, Jonathan I Silverberg |
Journal | The British journal of dermatology
(Br J Dermatol)
Vol. 188
Issue 6
Pg. 740-748
(05 24 2023)
ISSN: 1365-2133 [Electronic] England |
PMID | 36994947
(Publication Type: Randomized Controlled Trial, Clinical Trial, Phase III, Journal Article)
|
Copyright | © The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists. |
Chemical References |
- lebrikizumab
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Interleukin-13
- Immunoglobulin A
|
Topics |
- Adult
- Adolescent
- Humans
- Dermatitis, Atopic
(drug therapy, diagnosis)
- Antibodies, Monoclonal, Humanized
- Treatment Outcome
- Injections, Subcutaneous
- Double-Blind Method
- Severity of Illness Index
- Antibodies, Monoclonal
(adverse effects)
- Interleukin-13
- Immunoglobulin A
|